Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.33 -0.10 (-0.69%) Official Closing Price Updated: 7:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Takeda Pharmaceutical Ltd ADR < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices January 14, 2023 Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch... Via Talk Markets Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC January 11, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study January 09, 2023 Via Benzinga Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease January 09, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks January 06, 2023 Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too. Via Investor's Business Daily Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP) January 05, 2023 From Takeda Pharmaceutical Company Limited Via Business Wire A Bullish Sign Appears On Takeda Pharmaceutical's Chart December 28, 2022 Via Benzinga Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies December 14, 2022 Via Benzinga Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B December 13, 2022 Via Benzinga Takeda's Dengue Vaccine Candidate Under FDA Priority Review November 23, 2022 Via Benzinga Takeda Posts Lower 1H Profit, Lifts FY22 Outlook October 27, 2022 Via Benzinga Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics December 13, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting December 09, 2022 Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study Via Benzinga Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases December 09, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union December 08, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing December 06, 2022 From Singapore Economic Development Board (EDB)A*STAR Via ACN Newswire Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? November 30, 2022 Tech layoffs are in the news, but life sciences companies seem to be doing better. Via The Motley Fool Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease November 29, 2022 The company says it plans soon to present Phase 2 results and its Phase 3 study design. Via Investor's Business Daily Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration November 22, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved November 22, 2022 This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result... Via Benzinga Why Puma Biotechnology's Shares Jumped 20% on Monday November 21, 2022 It may have benefited from positive news about another company's drug candidate. Via The Motley Fool Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings November 17, 2022 Via Benzinga Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US November 17, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire 2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade November 16, 2022 Is now the time to load up on these high-yielding investments? Via The Motley Fool European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies November 11, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire Why Denali Therapeutics' Stock Rose 6.6% on Wednesday November 02, 2022 The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close. Via The Motley Fool Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast October 27, 2022 From Takeda Pharmaceutical Company Limited Via Business Wire 7 Dividend Stocks to Sell Pronto Before a Painful Downturn October 24, 2022 Investors may find many dividend stocks to sell, considering returns from the risk-free U.S. Treasury Bills often exceed their yield. Via InvestorPlace CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? October 20, 2022 Despite enthusiasm in some camps, the risk of potential cures clouds market projections. Via Investor's Business Daily Earnings Scheduled For October 27, 2022 October 27, 2022 Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.